Breast Cancer
From the Journals
Breast density alone should not prompt supplemental imaging discussions
From the Journals
Increased cancer death linked to radioactive iodine therapy
From the Journals
CVD risk upped in postmenopausal breast cancer survivors
Overall, breast cancer patients had significantly higher HSP60 levels and lower HSP70 levels than those of their cancer-free peers.
Conference Coverage
APHINITY trial: Biomarker analysis IDs predictive, prognostic factors
CHICAGO – Higher levels of several immune markers confer better prognosis in HER2-positive breast cancer patients treated with trastuzumab and...
How I will treat my next patient
Chemo-free neoadjuvant approaches emerge in NSCLC and breast cancer
Dr. Alan P. Lyss breaks down new data presented on immune checkpoint inhibitors in NSCLC and trastuzumab emtansine for HER2-positive breast cancer...
From the Journals
Novel chip system could improve preclinical drug studies
These chip systems could potentially reduce the use of animals and increase the efficiency of drug evaluations in preclinical studies.
Conference Coverage
PALOMA-3 biomarker analysis: Liquid biopsy could ID progression risk
TP53 mutation, FGFR1 amplification, and tumor purity in plasma each predict early progression on palbociclib and/or fulvestrant in patients with...
From the Journals
Niraparib-pembrolizumab combo finds niche in breast, ovarian cancers
The combination had good antitumor activity, as well as good safety and tolerability, in patients with advanced TNBC or ovarian carcinoma who were...
Conference Coverage
TAILORx: Clinical data add value to recurrence score
CHICAGO – Clinical risk stratification adds prognostic value to the 21-gene recurrence score for guiding treatment selection in patients with...
News
FDA approves trastuzumab-anns for HER2-positive breast, gastric cancer
This is the fifth FDA approval of a trastuzumab biosimilar.
Conference Coverage
Breast cancer linked to 23% higher risk for new diabetes
It’s a “clear signal” of extra risk, researcher says, but there’s no explanation yet.